TGF-beta/Smad in prostate cancer: an update.
- Author:
Ji ZHA
1
;
Yu-feng HUANG
Author Information
1. PLA Research Institute of Clinical Laboratory Medicine, Nanjing General Hospital of Nanjing Military Region, Nanjing, Jiangsu 210002, China.
- Publication Type:Journal Article
- MeSH:
Humans;
Male;
Prostatic Neoplasms;
metabolism;
Signal Transduction;
Smad Proteins;
metabolism;
Transforming Growth Factor beta;
metabolism
- From:
National Journal of Andrology
2009;15(9):840-843
- CountryChina
- Language:Chinese
-
Abstract:
Tumorigenesis and cancer progression are closely associated with the transforming growth factor-beta (TGF-beta) and its downstream component Smad. The TGF-beta/Smad signaling pathway, which is activated in prostate cancer, has a regulatory effect on cell adhesion, the actin filament system and cell cycle, as well as the expression of specific genes. Meanwhile, other protein signals such as MAPK and PI3K/Akt/mTOR and some genes may act on the expression of the TGF-beta/Smad pathway. This article updates recent researches on the expression, action and regulatory effect of the TGF-beta/Smad signaling pathway in prostate cancer.
